Page 82 - Read Online

Lo Re et al. J Cancer Metastasis Treat 2020;6:17 Journal of Cancer
DOI: 10.20517/2394-4722.2020.11 Metastasis and Treatment

Case Report Open Access

Cyclophosphamide, fluorouracil and low-
dose interleukin-2 and salvage combination

chemotherapy in advanced cutaneous squamous
cell carcinoma

Giovanni Lo Re , Paolo Doretto , Francesco Lo Re , Fabio Matrone , Anna Ermacora , Wally Marus , Maria
5
4
3
1
2
6
Antonietta Pizzichetta , Sandro Sulfaro 6
7
1 Medical Oncology and Immune-Related Tumors, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, PN 33081,
Italy.
2 Clinical Pathology, AAS5 Pordenonese, PN 33170, Italy.
3 Pharmacology and Clinical Toxicology, University of Milan, Milan, MI 20129, Italy.
4 Radiotherapy Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, PN 33081, Italy.
5 Internal Medicine, AAS5 Pordenonese, PN 33170, Italy.
6 Pathology, AAS5 Pordenonese, PN 33170, Italy.
7 Medical oncology and Cancer prevention, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, PN 33081, Italy.
Correspondence to: Dr. Giovanni Lo Re, Medical Oncology and Immune-Related Tumors, Centro di Riferimento Oncologico di
Aviano (CRO), IRCCS, Via Gallini 2, Aviano, PN 33081, Italy. E-mail: giovanni.lore@cro.it
How to cite this article: Lo Re G, Doretto P, Lo Re F, Matrone F, Ermacora A, Marus W, Pizzichetta MA, Sulfaro S. Cyclophosphamide,
fluorouracil and low-dose interleukin-2 and salvage combination chemotherapy in advanced cutaneous squamous cell
carcinoma. J Cancer Metastasis Treat 2020;6:17. http://dx.doi.org/10.20517/2394-4722.2020.11
Received: 31 Jan 2020 First Decision: 28 Apr 2020 Revised: 1 May 2020 Accepted: 26 May 2020 Published: 24 Jun 2020

Science Editor: Pravin D. Potdar Copy Editor: Cai-Hong Wang Production Editor: Tian Zhang

Abstract
A 70-year-old female with metastatic cutaneous squamous cell carcinoma (cSCC) and low-grade non-Hodgkin’s
lymphoma, not amenable to cisplatin combination therapy, was treated with cyclophoshamide (Cyc)-fluorouracil
(FU)-interleukin-2 (IL-2) in light of high tumor immunogenicity and the potential activity of this regimen. Cyc
2
2
300 mg/m and FU 500 mg/m intravenously on day 1 and IL-2 4.5 MIU/day on days 3-6 and 17-20
subcutaneously every 4 weeks; Carboplatin (C) AUC 2 and paclitaxel (P) 85 mg/m on days 1, 8 and 15 ±
2
capecitabine (Cape) every 4 weeks. After partial remission (PR) of lung metastases and local control with two
cycles of first therapy followed by PR with five cycles of CP ± Cape, right mastectomy was performed with
evidence of viable tumor. Subsequently, the patient underwent 3 cycles of chlorambucil and is alive after 13 months
of follow-up. Safety and activity of chemo-immunotherapy and salvage treatment can be achieved in cSCC.

Keywords: Cutaneous squamous cell carcinoma, cyclophosphamide, fluorouracil, interleukin-2, regulatory T cells,
myeloid-derived suppressor cells

© The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0
International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long
as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license,
and indicate if changes were made.

www.jcmtjournal.com